Skip to main content

Table 2 Efficacy of the HPV vaccine in women with CIN after 2 years of follow-up

From: Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial

Variable

Post-injection condition of the lesion after 2 years of follow-up

Efficacy (%)

*P value

Normal

CIN 1

CIN 2–3

N (%)

CIN 1

Control (N = 35)

16 (45.7)

19 (54.3)

–

54.9

0.02

Two more doses of vaccination (N = 45)

34 (75.6)

11 (24.4)

–

  

CIN 2

Controls (N = 35)

14 (40)

–

21 (60)

63.3

0.01

Two more doses of vaccination (N = 50)

39 (78)

–

11 (22)

  

CIN 3

**Controls (N = 34)

14 (41.2)

–

20 (58.2)

52.5

0.03

***Two more doses of vaccination (N = 43)

31 (72.1)

–

12 (27.9)

  
  1. Abbreviations: N Number; CIN Cervical intraepithelial neoplasia
  2. * Data were analyzed with Fisher’s exact test
  3. **One woman in the control group actually developed invasive cervical cancer
  4. ***All women with CIN 3 received 3 doses of the vaccination